CAR T-cell immunotherapy:a powerful weapon for fighting hematological B-cell malignancies

• 作者: Jian-Qing Mi Jie Xu Jianfeng Zhou Weili Zhao Zhu Chen J.Joseph Melenhorst Saijuan Chen
• 来源期刊: 医学前沿
• 年，卷（期）: 2021,（6）
• 所属期刊栏目: Review
• 页码范围: 783-804
• 页数: 22页
• 语种: 英文

摘要

The current standard of care in hematological malignancies has brought considerable clinical benefits to patients.However,important bottlenecks still limit optimal achievements following a current medical practice.The genetic complexity of the diseases and the heterogeneity of tumor clones cause difficulty in ensuring long-term efficacy of conventional treatments for most hematological disorders.Consequently,new treatment strategies are necessary to improve clinical outcomes.Chimeric antigen receptor T-cell(CAR T)immunotherapy opens a new path for targeted therapy of hematological malignancies.In this review,through a representative case study,we summarize the current experience of CAR T-cell therapy,the management of common side effects,the causative mechanisms of therapy resistance,and new strategies to improve the efficacy of CAR T-cell therapy.